Critical Review: Edap Tms (NASDAQ:EDAP) vs. Artivion (NYSE:AORT)

Edap Tms (NASDAQ:EDAP) and Artivion (NYSE:AORT) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, earnings, dividends, institutional ownership, valuation, profitability and analyst recommendations.

Earnings & Valuation

This table compares Edap Tms and Artivion”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Edap Tms	$70.53 million	2.23	-$29.25 million	($0.81)	-5.19
Artivion	$441.33 million	2.48	$9.77 million	$0.24	94.09

Artivion has higher revenue and earnings than Edap Tms. Edap Tms is trading at a lower price-to-earnings ratio than Artivion, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Edap Tms has a beta of -0.1, meaning that its stock price is 110% less volatile than the S&P 500. Comparatively, Artivion has a beta of 1.41, meaning that its stock price is 41% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Edap Tms and Artivion, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Edap Tms	1	1	1	0	2.00
Artivion	0	1	7	0	2.88

Edap Tms currently has a consensus price target of $6.00, indicating a potential upside of 42.86%. Artivion has a consensus price target of $47.83, indicating a potential upside of 111.82%. Given Artivion’s stronger consensus rating and higher probable upside, analysts plainly believe Artivion is more favorable than Edap Tms.

Profitability

This table compares Edap Tms and Artivion’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Edap Tms	-41.47%	-137.61%	-40.62%
Artivion	2.55%	7.15%	3.63%

Institutional & Insider Ownership

62.7% of Edap Tms shares are owned by institutional investors. Comparatively, 86.4% of Artivion shares are owned by institutional investors. 10.1% of Edap Tms shares are owned by insiders. Comparatively, 6.3% of Artivion shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Artivion beats Edap Tms on 13 of the 14 factors compared between the two stocks.

About Edap Tms

EDAP TMS SA is a holding company, which, through its subsidiary, engages in the development, production, and marketing of minimally invasive medical devices for urological diseases. It operates through the High Intensity Focused Ultrasound (HIFU) and Urology Devices and Services (UDS) segments. The HIFU segment develops, manufactures, and markets devices for the minimally invasive ablation of certain types of localized tumors using HIFU technology. The UDS segment focuses on the development, marketing, manufacturing, and servicing of medical devices for the minimally invasive diagnosis or treatment of urological disorders, mainly urinary stones, and other clinical indications. The company was founded on December 3, 1979 and is headquartered in Vaulx-en-Velin, France.

About Artivion

Artivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo. It offers E-xtra design engineering systems for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment of thoraco-abdominal disease; E-vita THORACIC 3G for the endovascular treatment of thoracic aortic aneurysms; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac to treat aneurysmal iliac arteries, and aneurysmal iliac side branches; and E-tegra, a stent graft system for the treatment of infrarenal abdominal aortic aneurysms. In addition, the company offers synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures; PerClot, an absorbable powdered hemostat for use in surgical procedures; cardiac laser therapy products for angina treatment; CryoVein femoral vein and CryoArtery femoral artery vascular preservation services; On-X prosthetic aortic and mitral heart valves and the On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures for mitral chordal replacement; and ascyrus medical dissection stents, as well as pyrolytic carbon coating services to medical device manufacturers. It serves physicians, hospitals, and other healthcare facilities, as well as cardiac, vascular, thoracic, and general surgeons. The company was formerly known as CryoLife, Inc. and changed its name to Artivion, Inc. in January 2022. Artivion, Inc. was incorporated in 1984 and is headquartered in Kennesaw, Georgia.